MBRX - Penny Stock Moleculin Highlights Interim Data From Blood Cancer Study With Complete Response Rate of 38% | Benzinga
Moleculin Biotech Inc (NASDAQ: MBRX) provided a preliminary update on recent clinical activity from annamycin lead development programs.
Annamycin is the company's next-generation anthracycline that has been designed to be non-cardiotoxic (unlike currently prescribed anthracyclines) and has been shown in animal models to accumulate in the lungs at up to 30-fold the level of doxorubicin (a commonly prescribed anthracycline and the standard of care chemotherapy for advanced STS).
It also ...